ICPT stock forecast
Our latest prediction for Intercept Pharmaceuticals, Inc.'s stock price was made on the April 9, 2018 when the stock price was at 69.24$.
In the short term (2weeks), ICPT's stock price should outperform the market by 1.84%. During that period the price should oscillate between -8.05% and +8.74%.
In the medium term (3months), ICPT's stock price should underperform the market by -0.24%. During that period the price should oscillate between -19.61% and +22.92%.
Get email alertsCreate a solid portfolio with ICPT
About Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
At the moment the company generates 272M USD in revenues.
On its last earning announcement, the company reported a loss of -10.72$ per share.
The book value per share is 4.96$
Three months stock forecastApril 9, 2018
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 272M | 98.40% | -312M | -114.50% | -347M | -10.72 | - | - | 32M | 4.96 | -252M | -1M | -253M |